European mega-caps trail US 'Magnificent 7' amid lack of AI gains, while also facing China’s slowdown and rising geopolitical ...

A groundbreaking Harvard study reveals that semaglutide could benefit more people in the U.S. than ever imagined.

Drugmakers are likewise reaching out to other employers with the message that treating obesity will ultimately save them money.

Kennedy has promised to "Make America Healthy Again" by tackling obesity with nutrition. Here's how he could rattle the ...

On October 22, Novo Nordisk (Novo) nominated semaglutide products, which include its popular drugs marketed as Ozempic for type 2 diabetes and ...

KOLs interviewed by GlobalData think that semaglutide can be a treatment option for non-diabetic CKD patients whose kidney ...

More than half of all American adults, almost 137 million people, could be candidates for the blockbuster GLP-1 drug ...

FRANKFURT (Reuters) - Healthcare executives and investors expect an uptick in initial public offerings and corporate ...

There’s no hard-and-fast rule for how long it’s safe to stay on Ozempic for weight loss. Novo Nordisk-sponsored studies lasting up to two years show that semaglutide is safe.

The first prescription for the drug in China will reportedly be issued at a public hospital in Shanghai this week and will ...

Patients in China will be able to purchase the blockbuster weight-loss drug Wegovy for 1,400 yuan, or about $193, just a ...

Novo Nordisk A/S shares slipped again on Tuesday, briefly erasing what was left of this year’s lofty gains, as concerns ...